Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Open Access
- 22 January 2008
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 8 (1), 17
- https://doi.org/10.1186/1471-2407-8-17
Abstract
Subclassification of ovarian carcinomas can be used to guide treatment and determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. The mechanism of BRCA1/2 loss is a potential method of subclassifying high grade serous carcinomas.Keywords
This publication has 83 references indexed in Scilit:
- DNA damage-induced cell death by apoptosisTrends in Molecular Medicine, 2006
- Expression profiling and individualisation of treatment for ovarian cancerCurrent Opinion in Pharmacology, 2006
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- Origins and molecular pathology of ovarian cancerLaboratory Investigation, 2005
- Highly multiplexed molecular inversion probe genotyping: Over 10,000 targeted SNPs genotyped in a single tube assayGenome Research, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Statistical Analysis of Adsorption Models for Oligonucleotide MicroarraysStatistical Applications in Genetics and Molecular Biology, 2004
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinomaCancer, 2003
- A physical map and candidate genes in the BRCA1 region on chromosome 17q12–21Nature Genetics, 1994